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abstract
Population aging is rapidly accelerating worldwide; however, longer life expectancy is not the only public 
health goal. Indeed, extended lifetime involves maintaining function and the capacity of living independently. 
Sarcopenia and physical frailty are both highly relevant entities with regards to functionality and autonomy of 
older adults. The concepts and definitions of frailty and sarcopenia have largely been revised over the years. 
Sarcopenia is an age-related progressive and generalized loss of skeletal muscle mass and strength. On the 
other hand, frailty is a state of increased vulnerability to stressors, responsible for exposing the older person 
to enhanced risk of adverse outcomes. Physical frailty and sarcopenia substantially overlap and several adverse 
outcomes of frailty are likely mediated by sarcopenia. Indeed, the concepts of sarcopenia and physical frailty can 
be perceived as related to the same target organ (i.e., skeletal muscle) and it may be possible to combine them 
into a unique definition. The biological background of such a close relationship needs to be explored and clarified 
as it can potentially provide novel and pivotal insights for the assessment and treatment of these conditions 
in old age. The aim of this paper is to indicate and discuss possible biological markers to be considered in the 
framing of physical frailty and sarcopenia.
background
A healthy musculoskeletal system is necessary 
for physical functioning. A decrease of skeletal 
muscle mass is a universal consequence of 
aging with a broad range of functional and 
metabolic consequences [1]. Skeletal muscle 
affects a wide spectrum of vital processes that 
are often inadequately appreciated [2]. Clearly, 
skeletal muscle is responsible for movement 
and loss of muscle mass and quality may result 
in weakness and reduced mobility; however, 
skeletal muscle is also the largest reserve of 
proteins in the body. During periods of stress, 
under-nutrition, or starvation, it provides a 
continuous supply of amino acids in order to 
support the protein synthesis for vital organs. 
Skeletal muscle represents the primary site of 
glucose disposal, as well. A reduction of muscle 
mass may cause metabolic dysregulation, 
especially in patients with insulin resistance and 
type 2 diabetes. In addition, skeletal muscle is 
the major energy consumer and contributor to 
basal metabolic rate in the body. Loss of muscle 
represents the primary cause of age-associated 
reduced basal metabolic rate and decreased 
energy needs [3]. 
The age-associated loss of skeletal muscle 
mass, function, and quality is commonly known 
as “sarcopenia” [4-7]. Sarcopenia (derived from 
Greek sarx for flesh and penia for loss) is a term 
coined by Rosenberg to describe one of the 
most noticeable changes occurring with aging 
[8]. It has been defined as the “progressive loss of 
muscle mass and strength with a risk of adverse 
outcomes such as disability, poor quality of life 
and death” by the Special Interest Group of the 
European Sarcopenia Working Group in 2010 
[9]. The term is used specifically to denote loss 
of muscle mass and strength associated with 
aging and distinguishes muscle loss due to 
aging from other causes, such as immobility or 
neurological damage. Sarcopenia is recognized 
as a geriatric syndrome and a key public health 
issue. Starting at the age of 30 years, individuals 
lose 1-2% of muscle per year, and by the age 
of 80 years, 30% of muscle mass is lost [10, 11]. 
The prevalence of low muscle mass is estimated 
to be between 10 and 25% depending on the 
studied population and methods applied. 
In octogenarians the prevalence increases 
up to 50% [9]. Reduced muscle function is 
independently associated with increased risk 
of functional impairment, falls, disability and 
mortality in older subjects [12].
Under normal circumstances, muscle 
homeostasis is maintained as a delicate 
balance between new muscle cell formation, 
hypertrophy, and protein loss. This balance is 
coordinated by the central nervous, endocrine, 
and immune systems. Behavioral factors 
(i.e., nutrition and physical activity) may 
also substantially modify these interactions. 
Every endogenous and exogenous stressor 
disrupting the homeostatic balance of older 
persons may trigger an acceleration of the 
sarcopenia phenomenon. 
Physical frailty is strongly linked to muscle 
mass and function. Frailty is a multi-system 
impairment associated with increased 
vulnerability to stressors and describes 
individuals who are at increased risk of adverse 
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health outcomes [13]. All experts unanimously 
agree on the theory of frailty and the need to 
push forward its study, thus promoting the 
implementation of the syndrome in clinics and 
research.  However, frailty cannot be limited 
to a physical domain; psychological, cognitive, 
emotional, social and spiritual factors contribute 
to frailty and need to be taken into account in 
its definition. Physical frailty characterizes the 
unique core condition between sarcopenia 
and frailty [1]. Research on physical frailty is far 
more advanced than research on other aspects 
of frailty. A phenotypic approach to physical 
frailty has been introduced in clinical practice 
[14]. An alternative model of accumulation 
of deficits has also been used for measuring 
frailty in elderly people [15, 16]. None of these 
approaches seems to yield similar results in 
clinical practice [17]. Nevertheless, there is 
an overall agreement about the key role that 
physical function plays in the determination of 
the status of extreme vulnerability [18-20].
A careful examination of concepts of 
sarcopenia and physical frailty shows that they 
share many common points [1]. In fact, several 
adverse outcomes of frailty and sarcopenia 
are likely associated and sometimes one 
may determine the other. Sarcopenia is also 
associated with modifications in biological 
functions, including inflammation, glucose 
regulation, hormone production, cellular 
communication and protein storage. In 
this regard, the identification of specific 
biological markers that can be quantified 
in a reliable and cost-effective manner is 
important. Such biomarkers may serve in the 
qualitative assessment of the physical function 
impairment, represent potential targets for 
interventions, and support the clinical and 
research follow-up of the condition of interest.
biological markers of physical 
frailty and sarcopenia
Definition of a biomarker
A biomarker is defined as “a characteristic 
that is objectively measured and evaluated as 
an indicator of normal biological processes, 
pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” [21]. 
The optimal biomarker should be quantified 
in an accurate and reproducible manner and 
the assay feasible at reasonable cost. It should 
add new information that cannot be obtained 
by a careful clinical assessment alone. More 
importantly, the biomarker needs to show a 
strong correlation between the disease and its 
outcome in clinical studies. The ideal biomarker 
should support the clinician’s decisions in the 
management of the condition of interest. 
Last but not least, a biomarker can be used 
in research trials, making it more suitable 
for screening, baseline evaluation, and/or 
definition of outcomes. There are biomarkers 
for screening (to identify the target population), 
for assessment, and for follow-up. For example, 
biomarkers for detection and diagnosis may 
not be the same as those that ideally track 
disease progression. A biomarker is defined 
as any substance, structure, or process that 
can be measured in the body or its products, 
influence or predict the incidence of outcome 
or disease, and can be used in research. In this 
definition, biological markers “(blood, urine, 
etc.), functional tests or imaging markers are 
included. In this paper, we will only focus on 
biological markers of sarcopenia and physical 
frailty.
Sarcopenia may be considered a biological 
substrate for the development of physical 
frailty. In this context, several biological markers 
have been shown to be associated with skeletal 
muscle mass, strength, and function, thus 
representing potential markers for the effect 
of the studied interventions. There is not only 
one biological marker that perfectly matches 
the sarcopenia and physical frailty criteria, but 
there is a range of complementary biomarkers, 
that will together constitute the ideal panel of 
markers (Fig. 1).
elevated inflammatory markers 
associated with lower muscle 
mass and strength
In older age, a low-grade inflammatory state 
characterized by increased concentrations of 
cytokines and acute phase proteins is common 
[22, 23]. TNF-α, IL-1β, IL-6, and IL-18, and 
C-reactive protein (CRP) and fibrinogen are 
among the cytokines and acute phase proteins 
that have been frequently studied in describing 
such chronic inflammatory states [24]. This 
phenomenon, also called “inflammaging,” 
results from an imbalance between pro- and 
anti-inflammatory networks [25]. Muscle mass 
and strength are inversely associated with 
plasma concentrations of IL-6 and TNF-α in 
well-functioning older men and women [26-
28], which is only partially explained by decline 
in muscle strength and slowed walking speed 
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[29]. Moreover, elevated inflammatory markers 
predict mobility limitation, independent of 
cardiovascular disease events and severe illness 
[30]. 
products of oxidative damage 
contribute to sarcopenia and 
physical frailty
One of the factors that could play a key role 
in triggering sarcopenia and physical frailty is 
the accumulation of reactive oxygen species 
(ROS). ROS are generated by the addition of a 
single electron to the oxygen molecule. ROS 
are by-products found in practically all tissues 
and are usually generated in the mitochondrial 
respiratory chain. Such reactive elements are 
often harmful, resulting in oxidative stress that 
can damage other cellular components such as 
DNA, proteins, lipids, etc., which in turn results 
in subsequent damage to cells and tissues. Cells 
respond to oxidative stress by variations in the 
rate of cell growth, changes in cell cycle length, 
and increase of their defensive mechanisms 
(i.e. antioxidant defense system). Free radicals 
cause severe damage if they are not promptly 
eliminated by the action of anti-oxidant agents. 
The levels of these damaged macromolecules 
and lipids increase with age [31, 32]. 
Protein carbonyls are known markers of 
oxidative stress and accumulate with aging 
[33]. Protein carbonylation leads to cellular 
dysfunction and a decline in tissue function 
and is involved in the pathogenesis of 
sarcopenia [34]. Serum protein carbonyls are 
independently associated with grip strength 
[35].
Advanced glycation end products (AGEs), 
bioactive compounds that are formed by 
nonenzymatic glycation of proteins, lipids, 
and DNA, play a role in the pathogenesis of 
sarcopenia and physical frailty [36]. Elevated 
serum AGEs are associated with poor muscle 
strength [37].
serum creatinine and urinary 
creatinine excretion as a marker 
of muscle mass
Creatine is a naturally occurring nitrogen-
containing compound found in the diet, 
primarily in red meat and seafood [38]. The 
majority of creatine is stored in skeletal muscle 
as phosphocreatine (PCr), a high-energy 
phosphate involved in the rapid resynthesis of 
adenosine triphosphate (ATP) during intense 
muscle contraction [38]. Aging may have a 
negative impact on high-energy phosphate 
metabolism [39-41]. 
Creatine is the precursor of creatinine. In the 
steady-state and with stable kidney function, 
creatinine is usually produced at a relatively 
constant rate by the body depending on 
the absolute amount of muscle mass [42]. 
Creatinine is filtered out of the blood by the 
glomeruli (and is excreted to a smaller extent 
in the proximal tubules of the kidney). Since 
there is little to no tubular reabsorption of 
creatinine, its renal clearance is often used 
to estimate glomerular filtration rate. Under 
stable kidney function, the serum or plasma 
concentration of serum creatinine can also 
reflect skeletal muscle mass, if its non-muscle-
mass-dependent variations (such as due to 
renal filtration or meat intake) can be accurately 
accounted for [42]. 
A new biological technique to estimate 
muscle mass has been developed recently by 
using a dose of creatine labelled with a non-
radioactive tracer (deuterium). The isotope, 
enclosed in a gel capsule is ingested, and a 
urine sample collected several days later is 
used to estimate deuterated creatine by mass 
spectroscopy. The measured dilution space 
is strongly correlated with total body skeletal 
muscle mass measured with MRI [43]. 
To the best of our knowledge, the 
relationship between serum or urinary 
creatinine excretion and muscle strength has 
not been demonstrated. However, several 
studies provided evidence for the effects of 
creatine supplementation on muscle strength 
[44, 45].
endocrine function
Decline in muscle mass and parallel decline of 
muscle function are attributed to a progressive 
shift from anabolic to catabolic metabolism 
with a reduced capacity for synthesizing new 
proteins and repairing muscle damage [46]. 
The defect in muscle protein homeostasis may 
be related to changes in circulating levels of 
hormones. 
The age-associated decline in the production 
of dehydroepiandrosterone sulfate (DHEAS) is 
an important determinant of reduced muscle 
mass and strength in older persons [47]. There 
is evidence that sex hormones (testosterone, 
estrogens, and DHEAS), whose levels decrease 
with age, exert an important role in the age-
related onset of sarcopenia [48]. DHEAS may 
affect muscle performance. The skeletal muscle 
is able to convert DHEA into active androgens 
and estrogens, and to stimulate insulin-like 
growth factor-1 (IGF-1), which is important 
for muscle growth and recovery [49]. The 
maintenance of adult muscle depends on 
satellite cell activation, proliferation, survival, 
and differentiation, all of which can also be 
stimulated by testosterone [50, 51]. The effects 
of testosterone on muscle can be categorized 
as anabolic, anti-catabolic, and potentially anti-
inflammatory [52, 53]. 
It has been proposed that testosterone 
stimulates skeletal muscle protein synthesis, 
improve recycling of intracellular amino acids, 
and promote the activity of motor neurons [52]. 
However, the proposed effects of testosterone 
on muscle protein degradation are not 
straightforward. It appears that short-term 
testosterone administration does not change 
the breakdown rate of muscle proteins, whereas 
treatment for several months decreases 
muscle protein breakdown [52]. Testosterone 
promotes commitment of pluripotent stem 
cells to myogenic lineage but inhibits their 
differentiation into adipocytes via an androgen 
receptor-mediated pathway, suggesting the 
rationale for its well-known effects on the 
reduction in body fat mass and the increase in 
fat-free mass and insulin sensitivity [54].
The link between vitamin D and skeletal 
muscle health has been well-described in 
clinical studies [55]. There is a broad range 
of muscle deficits associated with varying 
degrees of vitamin D insufficiency, whereas 
supplementation with various forms of 
vitamin D has mostly beneficial effects. 
The identification of the vitamin D receptor 
(VDR) in skeletal muscle tissue provides solid 
evidence for its direct effect on physical frailty 
and sarcopenia [56, 57]. Some studies have 
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identified genomic effects of vitamin D, leading 
to the synthesis of new proteins that affect 
muscle cell contractility, proliferation, and 
differentiation [58, 59]. 
Loss of skeletal muscle mass has also been 
associated with insulin resistance and high 
glycated hemoglobin HbA1C concentrations. 
Skeletal muscle is a primary tissue responsible 
for insulin-mediated glucose disposal; thus, 
low muscle mass may cause reduced insulin-
mediated glucose disposal. However, type II 
muscle fibers, which are less responsive to the 
metabolic actions of insulin [60], are lost to a 
greater extent than type I fibers in age-related 
muscle atrophy [61]. Moreover, some studies 
have shown that insulin resistance precedes 
the development of frailty [62-65].
urine proteomics panel of 
muscle protein breakdown: 
measure of muscle catabolism
Urinary proteins should be regarded as a 
potential source of biomarkers for several 
disorders of muscle catabolism. Over the past 
few years, great technological advances have 
occurred in proteomics, and a large number 
of proteins in the urinary proteome of healthy 
people have been identified [65-69]. Thus far, 
protein–protein interaction data (interactome) 
has been widely used for the identification 
of biomarkers, with the assumption that 
the interactions of proteins may well reflect 
the health status. More than a biomarker, 
measurement of urine proteomics panel of 
muscle protein breakdown is a technique for 
simultaneously assessing multiple biomarkers 
and seeing how they interact.
n-terminal procollagen 
peptides: measure of muscle 
fibrosis 
Type III collagen in soft connective tissues, 
such as muscle and skin, is synthesized from 
larger procollagen III molecules carrying 
peptide extensions at both N- and C-terminal 
ends [70-72]. The N- and C-terminal extensions 
of procollagen III are removed by specific 
proteinases during the final stages of collagen 
synthesis, and released into the circulation in 
stoichiometric amounts [72]. Procollagen type 
III N-terminal peptide (P3NP), a product of this 
proteolytic cleavage during collagen synthesis 
in connective tissue, can be measured in the 
human serum, and its circulating concentrations 
have been described in children, healthy 
adults, acromegalic subjects, and athletes [73-
77]. P3NP levels vary in response to exercise, 
testosterone, and growth hormone (GH) [75, 
78-82], and could represent useful markers 
of GH doping in sports [75, 76, 80-85]. Plasma 
concentrations of P3NP represent an interesting 
marker of skeletal muscle remodeling. Indeed, 
serum P3NP concentrations reflect lean body 
mass and appendicular skeletal muscle mass 
[86].
overexpression of myostatin 
leads to muscle atrophy 
Myostatin is a member of the transforming 
growth factor-b superfamily and is known 
to be a negative regulator of skeletal muscle 
myogenesis and functions as an inhibitor of 
muscle growth [87-89]. Myostatin-deficient 
mice have increased muscle mass, whereas 
overexpression of myostatin leads to muscle 
atrophy [88, 90]. Although alterations in 
myostatin expression and activity in the 
context of aging are not fully understood, 
aging is associated with upregulated myostatin 
expression in humans [91]. Thus, older 
myostatin null mice exhibit resistance to the 
sarcopenic phenotype [92-94] and neutralize 
antibodies to myostatin, leading to an increase 
in muscle mass and improved measures of 
muscle performance, including grip strength 
[95-97]. 
agrin fragment: measure of 
neuromuscular junction function 
Agrin, an extracellular proteoglycan, is 
synthesized in motor neurons, transported 
along the axons and finally released into 
the synaptic basal lamina, where it induces 
postsynaptic differentiation (including 
acetylcholine receptor clustering). Agrin is 
therefore essential for the formation and 
stabilization of neuromuscular junctions 
[98]. Agrin is inactivated after cleavage by 
neurotrypsin, a synaptic protease, which frees 
a soluble 22 kDa C-terminal agrin fragment 
(CAF) that can be detected in human serum 
[99-101]. Experiments with transgenic mice 
overexpressing neurotrypsin in spinal motor 
neurons have shown the full sarcopenia 
phenotype, including a reduced number of 
muscle fibers, increased heterogeneity of fiber 
thickness, more centralized nuclei, fiber-type 
grouping and an increased proportion of type 
I fibers [102]. Thus, elevated levels of CAF cause 
degeneration of neuromuscular junctions and 
indicate that sarcopenia contributes to physical 
frailty.
which biomarker is more 
reflective of sarcopenia and 
physical frailty?
Given the syndromic nature of sarcopenia 
and physical frailty, no unique biomarker 
has all the features to reflect sarcopenia and 
physical frailty, but a panel of complementary 
biomarkers (likely belonging to multiple classes: 
imaging, biological markers, and functional 
tests) would be most useful. Together they 
constitute the ideal panel of markers. The first 
objective is to evaluate current biomarkers 
(described above) and the thresholds for 
correlation with clinical outcome, and perhaps 
with therapeutic intervention in clinical trials. 
The results of these trials will tell us whether 
biomarkers and thresholds can be upheld in 
accordance to the above-mentioned criteria 
for good biomarkers. It is likely that some of the 
suggested thresholds will have to be adjusted. 
The second objective is to identify novel 
biomarkers of sarcopenia. Biomarkers derived 
from blood or urine can easily be measured 
in a standardized and low-cost way and are 
therefore very attractive. Finally, further studies 
are necessary to understand how sarcopenia 
and physical frailty intersect with muscle tissue 
and to define specific biomarkers according to 
their relevance (diagnosis, follow-up, research, 
etc.).
conclusion
The recognition of sarcopenia as a major 
component of physical frailty implies that 
interventions that target the skeletal muscle 
Translational Neuroscience
107
may provide therapeutic and preventive 
advantages against frailty and its clinical 
correlates. Observational studies and some 
randomized clinical trials have suggested 
a positive effect of regular physical activity 
and nutritional interventions on improving 
physical function and/or reducing symptoms 
of disability in healthy older individuals and 
those at risk for mobility disability [103]. In this 
context, one research priority is to investigate 
and define novel biomarkers allowing an 
improved assessment, characterization and 
follow-up of elderly people with physical 
frailty and sarcopenia. It is necessary to 
identify a segment of the aging population 
at risk for adverse outcomes whose medical 
needs are presently unmet, partly due to the 
current unclear definition of frailty. We have 
to investigate the possibility of translating 
the model of physical frailty and sarcopenia 
into a clinical intervention (e.g. multidomain 
intervention) with potentially positive effects 
aimed at preventing mobility disability. The 
results generated by these studies will have 
relevant clinical and public health implications, 
filling an important gap in knowledge for 
practicing evidence-based geriatric medicine.
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